RUNX1 gene alterations are associated with acquired and inherited hematologic malignancies that include familial platelet disorder/acute myeloid leukemia, primary or secondary acute myeloid leukemia, and chronic myelomonocytic leukemia. Recently, we reported that RUNX1-mediated silencing of nonmuscle myosin heavy chain IIB (MYH10) was required for megakaryocyte ploidization and maturation. Here...

In a significant proportion of patients with chronic myeloid leukemia, resistance to BCR-ABL tyrosine kinase inhibitors develops due to acquisition of BCR-ABL kinase domain mutations and insensitivity of leukemia stem cells to tyrosine kinase inhibitors. Omacetaxine mepesuccinate (formerly called homoharringtonine) is a natural alkaloid that inhibits protein synthesis and induces cell death. Om...

During aging phenotypic changes in the hematopoietic system occur, and possible reason of these can be accumulation gene mutations stem cells or early blood progenitors. Although are mostly neutral, some may give progenitor a proliferative advantage. In this case clonal hematopoiesis will arise, which is characterized by formation genetically distinct subpopulation cells. Clonal become basis fo...

Acute myeloid leukemia is characterized by a malignant proliferation of hematopoietic progenitor cells of the myeloid lineage. The lack of differentiation of precursor cells causes their inability to function normally and the disruption of normal hematopoiesis. This review provides a brief overview of the most important pharmacological strategies that impact on acute myeloid leukemia cure rates...

PTEN deletion in the mouse and in the zebrafish highlights the essential role of this tumor suppressor in the development of myeloid malignancies, in particular acute myeloid leukemia and myeloproliferative disorders. In humans, extensive genetic sequences of myeloid malignancies did not reveal recurrent PTEN mutations and deletions. However, PTEN was shown to be functionally inactivated in sev...

6507]. J Clin Oncol. 2006;24(18)(suppl). 10. Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011;117(4):1141-1145. 11. Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in t...

Advances in the molecular characterization of leukemic cells have greatly improved the precision of diagnosis and treatment assignment as well as the monitoring of residual disease in both acute lymphoblastic leukemia and acute myeloid leukemia. Currently, specific genetic rearrangements can be identified in as many as 50% of children with either acute lymphoblastic leukemia or acute myeloid le...

24Boyse, E. A., L. J. Old, G. Geering, and E. Stockert, unpublished observations. 25 Cells from 4 cases of human leukemia (acute leukemia in a child, acute myeloid leukemia, chronic myeloid leukemia, and chronic lymphatic leukemia) were obtained through the courtesy of Dr. B. Clarkson, Dr. L. Murphy, and Dr. C. Tan of Sloan-Kettering Institute. These cells did not acquire sensitivity to Rausche...